Li Watsek

Stock Analyst at Cantor Fitzgerald

(0)
# 4775
Out of 5,270 analysts
89
Total ratings
32.93%
Success rate
-22.36%
Average return
Main Sectors:
Top Industries:
20 Stocks
Name Action Price Target Current % Upside Ratings Updated
Ascendis Pharma
Maintains: Overweight
170 200
154.62 29.35% 17 Feb 25, 2025
Arvinas
Reiterates: Overweight
n/a
n/a n/a 5 Feb 7, 2025
Acrivon Therapeutics
Initiates Coverage On: Overweight
n/a
n/a n/a 1 Jan 31, 2025
ALX Oncology Holding...
Reiterates: Overweight
n/a
n/a n/a 7 Jan 24, 2025
IDEAYA Biosciences
Reiterates: Overweight
n/a
n/a n/a 2 Jan 13, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Overweight
n/a
n/a n/a 10 Dec 9, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Overweight
n/a
n/a n/a 7 Nov 19, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Overweight
n/a
n/a n/a 4 Oct 7, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Overweight
20 20
5.26 280.23% 2 Sep 9, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Overweight
n/a
n/a n/a 5 Sep 9, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Overweight
n/a
n/a n/a 1 May 15, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Overweight
n/a
n/a n/a 5 Apr 9, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Overweight
n/a
n/a n/a 5 Apr 1, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Overweight
3
1.16 158.62% 4 Nov 22, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Overweight
220
4.14 5214.01% 3 Sep 7, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Neutral
26
n/a n/a 3 Sep 7, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Neutral
5
1.01 395.05% 3 Sep 7, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Overweight
1140
2.97 38283.84% 2 Sep 7, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
60 38
1.66 2189.16% 1 Aug 12, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
75 69
n/a n/a 2 Aug 9, 2022